Exploiting disease genomics to catalyse new medicines

Details

Home

SGC Symposium:
Exploiting disease genomics to catalyse new medicines

Registration

Registration closes Sunday 3^rd June at 23:00 UK time

Please use this link to register and pay the relevant registration fee (£100 for industry or £50 for Academic/Charity/Non-Industry).

When you have registered we will store your details and contact you in due course with more information.

About

Development of novel medicines requires new, well-validated drug targets. Modern genetic studies and disease genomics suggest numerous new targets, but the translation of this knowledge to drug development projects is hampered by the lack of reagents and the high risk at early stages. The SGC’s Target Enabling Packages (TEPs) programme sets out to provide the basic toolkit (proteins, assays, crystal structures) and initial chemical matter needed to develop specific small molecules.

This symposium marks 3 years of our TEP project and will bring together our large international network of partners from academia and industry, to explore the use of novel reagents and launch ambitious compound development and translational projects. Its programme will cover recent advances, showcase novel potential targets for research, and establish new collaborations.

Programme

Speakers include: Paul Workman (ICR), Mike Ferguson (Dundee), Philippe Sanseau (GSK/Open Targets), Steve O'Rahilly (Cambridge), David Collier (Eli Lilly), David Tapolczay (LifeArc), Simon Ward (Cardiff), Gregg Morin (UBC). For more details please click on the Programme tab, above.

Poster session

There will be a poster competition in a room next to the main lecture theatre on the day. If you would like to have poster displayed please email jonathan.lowe@sgc.ox.ac.uk with a title and draft abstract by 11^th May. We will then let you know shortly after this if your poster has been selected and you can print it for the event. The poster size will be A0 and portrait orientation.

Useful information

The event is an all-day event and will open at 08:00 for a 08:30 start. The event will finish at 18:00.
The price includes a sit-down lunch and refreshments throughout the day.
The accompanying workshop on fragment screening, which was originally, scheduled for 15^th June, has now been postponed.

Programme

"Exploiting disease genomics to catalyse new medicines"
08:00	Registration
08:30	Gavin Screaton, University of Oxford	Welcome/Opening remarks

	Session 1: How do we select the best targets?
	Chair: Opher Gileadi
08:45	Opher Gileadi, University of Oxford	Introduction to the meeting
09:00	Paul Workman, The Institute of Cancer Research	Learning from Indiana Jones: Choose wisely in selecting targets and chemical probes
09:30	Jenny Taylor, University of Oxford	Using genomics to inform target selection
09:55	Philippe Sanseau, Open Targets	Selecting targets using Open Targets data
10:20	Coffee and posters

	Session 2: Understanding disease mechanisms
	Chair: Wyatt Yue
11:00	Steve O'Rahilly, University of Cambridge	Understanding the causes and consequences of obesity
11:30	David Collier, Eli Lilly	New target discovery and qualification using genome-scale data
11:55	Izabella Pena, The Children's Hospital of Eastern Ontario	Targeting aminoadipate-semialdehyde synthase (AASS) for pyridoxine-dependent epilepsy (PDE)
12:20	Liz Carpenter, University of Oxford	A TEP for DPAGT1: from protein glycosylation diseases to antibiotic design
12:45	Lunch and posters
13:40	Lunchtime workshop	Introduction to XChem - Anthony Bradley, University of Oxford

	Session 3: How do we enable early-stage drug discovery?
	Chair: Alex Bullock
14:00	Joseph Newman, University of Oxford	Targeting DNA repair pathways for cancer therapeutics : From structures to TEPs and beyond
14:25	Jennifer Ward, University of Oxford	Chemoproteomics as a tool in drug discovery
14:50	Gregg Morin, University of British Columbia	Proteogenomic characterization of CDK12 functions using a novel inhibitor
15:15	Simon Ward, Cardiff University	Neuropsychiatry - can we do better
15:40	Coffee and posters

	Session 4: How do we address unmet clinical need?
	Chair: Liz Carpenter
16:20	David Tapolczay, LifeArc	How can the biomedical community in the UK exploit TEPs?
16:45	Wen Hwa Lee, Structural Genomics Consortium	We should all be I'MPATIENT - Open Science to accelerate discoveries with patient and disease foundations
17:00	David Jenkinson, The Brain Tumour Charity	Building partnerships to target a rare paediatric glioma
17:15	Mike Ferguson, University of Dundee	No substitute for activity!
17:40	Chas Bountra, University of Oxford	Closing remarks